Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy Bicycle Therapeutics (BCYC) stocks in Canada

Learn how to easily invest in Bicycle Therapeutics stocks.

Bicycle Therapeutics is a biotechnology business based in the US. Bicycle Therapeutics stocks (BCYC.US) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was $31.02 – a decrease of 0.64% over the previous week. Bicycle Therapeutics employs 109 staff and has a trailing 12-month revenue of around $11.8 million.

How to buy shares in Bicycle Therapeutics

  1. Compare share trading platforms. Use our comparison table to help you find a platform that fits you.
  2. Open your brokerage account. Complete an application with your details.
  3. Confirm your payment details. Fund your account.
  4. Research the stock. Find the stock by name or ticker symbol – BCYC – and research it before deciding if it's a good investment for you.
  5. Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
  6. Check in on your investment. Optimize your portfolio by tracking your stock.

Bicycle Therapeutics stock price (NASDAQ:BCYC)

Use our graph to track the performance of BCYC stocks over time.

Bicycle Therapeutics shares at a glance

Information last updated 2022-01-25.
Latest market close$46.33
52-week range$20.67 - $62.08
50-day moving average $54.57
200-day moving average $41.23
Wall St. target price$73.33
PE ratio N/A
Dividend yield N/A (0%)
Earnings per share (TTM) $-2.87

Compare online stock trading platforms

Note: The dollar amounts in the table below are in Canadian dollars.

Name Product Finder Rating Stock Trading Fee Account Fee Available Asset Types Offer
FREE TRADES
Wealthsimple Trade
Finder Rating:
★★★★★
3.9 / 5
$0
$0
Stocks, ETFs
Get 2 free stocks when you deposit and trade $150.
Scotia iTRADE
Finder Rating:
★★★★★
3.8 / 5
$4.99 - $9.99
$0
Bonds, Options, Mutual Funds, ETFs, GICs, International Equities
Interactive Brokers
Finder Rating:
★★★★★
4.1 / 5
Min. $1.00, Max. 0.5%
$0
Stocks, Bonds, Options, ETFs, Currencies, Futures
OFFER
CIBC Investor's Edge
Finder Rating:
★★★★★
4 / 5
$4.95 - $6.95
$0 if conditions met, otherwise $100/year
Stocks, Bonds, Options, Mutual Funds, ETFs
Get up to $2,000 cash back. Conditions apply. Offer ends March 1, 2022.
Questrade
Finder Rating:
★★★★★
4.2 / 5
$4.95 - $9.95
$0
Stocks, Bonds, Options, Mutual Funds, ETFs, GICs, International Equities, Precious Metals
Get $50 in free trades when you fund your account with a minimum of $1,000.
Qtrade Direct Investing
Finder Rating:
★★★★★
4.1 / 5
$6.95 - $8.75
$0 if conditions met, otherwise $25/quarter
Stocks, Bonds, Options, Mutual Funds, ETFs, GICs
Get up to $5,000 cash back. Conditions apply. Offer ends March 1, 2022.
loading

Compare up to 4 providers

Online stock trading

Is it a good time to buy Bicycle Therapeutics stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

Bicycle Therapeutics price performance over time

Historical closes compared with the close of $46.33 from 2022-01-25

1 week (2022-01-19) -0.64%
1 month (2021-12-23) -23.13%
3 months (2021-10-26) -13.77%
6 months (2021-07-26) 34.45%
1 year (2021-01-26) 72.68%
2 years (2020-01-24) 330.98%
3 years (2019-01-22) N/A
5 years (2017-01-22) N/A

Bicycle Therapeutics financials

Revenue TTM $11.8 million
Gross profit TTM $-22,759,000
Return on assets TTM -17.9%
Return on equity TTM -47.23%
Profit margin 0%
Book value $6.67
Market capitalisation $1.4 billion

TTM: trailing 12 months

Bicycle Therapeutics share dividends

We're not expecting Bicycle Therapeutics to pay a dividend over the next 12 months.

Bicycle Therapeutics share price volatility

Over the last 12 months, Bicycle Therapeutics's shares have ranged in value from as little as $20.6701 up to $62.075. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Bicycle Therapeutics's is -0.2565. This would suggest that Bicycle Therapeutics's shares have been inversely-correlated to the average (for this exchange) – so when the broader market trended up or down, Bicycle Therapeutics has bucked the trend.

Bicycle Therapeutics overview

Bicycle Therapeutics plc, a clinical-stage biopharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics. Its lead product candidate is BT1718, a bicycle toxin conjugate (BTC), which is in Phase I/IIa clinical trials targeting tumors that express Membrane Type 1 matrix metalloprotease. The company's oncology product candidates also comprise BT5528, a BTC that is in a Phase I/IIa clinical trial targeting EphA2; BT8009, which is in preclinical studies targeting Nectin-4; and CD137, an immune cell co-stimulatory molecule that is in preclinical stage. In addition, it is developing THR-149, a plasma kallikrein inhibitor that completed Phase I clinical trials for the treatment of diabetic macular edema. Further, the company collaborates with biopharmaceutical companies and organizations to develop programs in therapeutic areas, such as anti-infective, cardiovascular, ophthalmology, and respiratory indications. It has a clinical trial and license agreement with the Cancer Research Technology Limited and CRUK; research collaboration agreements with AstraZeneca, Sanofi, Oxurion, and the Dementia Discovery Fund; and discovery collaboration and license agreement with Genentech for the discovery and development of Bicycle peptides for multiple immuno-oncology targets. Bicycle Therapeutics plc was incorporated in 2009 and is headquartered in Cambridge, the United Kingdom.

Frequently asked questions


Disclaimer: This information should not be interpreted as an endorsement of futures, stocks, ETFs, options or any specific provider, service or offering. It should not be relied upon as investment advice or construed as providing recommendations of any kind. Futures, stocks, ETFs and options trading involves substantial risk of loss and therefore are not appropriate for all investors. Trading forex on leverage comes with a higher risk of losing money rapidly. Past performance is not an indication of future results. Consider your own circumstances, and obtain your own advice, before making any trades.

More on investing

More guides on Finder

Go to site